Albert P. Li - Transporters and Drug-Metabolizing Enzymes in Drug Toxicity

207 207 Honig PK, Wortham DC, Lazarev A, Cantilena LR. Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine. J Clin Pharmacol 1996; 36(4):345–51.

208 208 Rau SE, Bend JR, Arnold MO, Tran LT, Spence JD, Bailey DG. Grapefruit juice‐terfenadine single‐dose interaction: magnitude, mechanism, and relevance. Clin Pharmacol Ther 1997; 61(4):401–9.

209 209 Kohlroser J, Mathai J, Reichheld J, Banner BF, Bonkovsky HL. Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration. Am J Gastroenterol 2000; 95(1):272–6.

210 210 Gitlin N, Julie NL, Spurr CL, Lim KN, Juarbe HM. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med 1998; 129(1):36–8.

211 211 Herrine SK, Choudhary C. Severe hepatotoxicity associated with troglitazone. Ann Intern Med 1999; 130(2):163–4.

212 212 Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005; 4(6):489–99.

213 213 Meier Y, Cavallaro M, Roos M, Pauli‐Magnus C, Folkers G, Meier PJ, et al. Incidence of drug‐induced liver injury in medical inpatients. Eur J Clin Pharmacol 2005; 61(2):135–43.

214 214 Bjornsson ES, Bergmann OM, Bjornsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug‐induced liver injury in the general population of Iceland. Gastroenterology. 2013; 144(7):1419–25, 25 e1‐3; quiz e19‐20.

215 215 Faich GA, Moseley RH. Troglitazone (Rezulin) and hepatic injury. Pharmacoepidemiol Drug Saf 2001; 10(6):537–47.

216 216 Dixit VA, Bharatam PV. Toxic metabolite formation from Troglitazone (TGZ): new insights from a DFT study. Chem Res Toxicol 2011; 24(7):1113–22.

217 217 Prabhu S, Fackett A, Lloyd S, McClellan HA, Terrell CM, Silber PM, et al. Identification of glutathione conjugates of troglitazone in human hepatocytes. Chem Biol Interact 2002; 142 (1–2):83–97.

218 218 Honma W, Shimada M, Sasano H, Ozawa S, Miyata M, Nagata K, et al. Phenol sulfotransferase, ST1A3, as the main enzyme catalyzing sulfation of troglitazone in human liver. Drug Metab Dispos 2002; 30(8):944–9.

219 219 Kostrubsky VE, Sinclair JF, Ramachandran V, Venkataramanan R, Wen YH, Kindt E, et al. The role of conjugation in hepatotoxicity of troglitazone in human and porcine hepatocyte cultures. Drug Metab Dispos 2000; 28 (10):1192–7.

220 220 Masubuchi Y. Metabolic and non‐metabolic factors determining troglitazone hepatotoxicity: a review. Drug Metab Pharmacokinet 2006; 21(5):347–56.

221 221 Smith MT. Mechanisms of troglitazone hepatotoxicity. Chem Res Toxicol 2003; 16(6):679–87.

222 222 Tafazoli S, Spehar DD, O'Brien PJ. Oxidative stress mediated idiosyncratic drug toxicity. Drug Metab Rev 2005; 37(2):311–25.

223 223 Galati G, Tafazoli S, Sabzevari O, Chan TS, O'Brien PJ. Idiosyncratic NSAID drug induced oxidative stress. Chem Biol Interact 2002; 142 (1–2):25–41.

224 224 Shibuya A, Watanabe M, Fujita Y, Saigenji K, Kuwao S, Takahashi H, et al. An autopsy case of troglitazone‐induced fulminant hepatitis. Diabetes Care 1998; 21 (12):2140–3.

225 225 Uetrecht J. Drug metabolism by leukocytes and its role in drug‐induced lupus and other idiosyncratic drug reactions. Crit Rev Toxicol 1990; 20(4):213–35.

226 226 Funk C, Pantze M, Jehle L, Ponelle C, Scheuermann G, Lazendic M, et al. Troglitazone‐induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (BSEP) by troglitazone and troglitazone sulfate. Toxicology 2001; 167(1):83–98.

227 227 Funk C, Ponelle C, Scheuermann G, Pantze M. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone‐induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (BSEP) in the rat. Mol Pharmacol 2001; 59(3):627–35.

228 228 Okada R, Maeda K, Nishiyama T, Aoyama S, Tozuka Z, Hiratsuka A, et al. Involvement of different human glutathione transferase isoforms in the glutathione conjugation of reactive metabolites of troglitazone. Drug Metab Dispos 2011; 39 (12):2290–7.

229 229 Hewitt NJ, Lloyd S, Hayden M, Butler R, Sakai Y, Springer R, et al. Correlation between troglitazone cytotoxicity and drug metabolic enzyme activities in cryopreserved human hepatocytes. Chem Biol Interact 2002; 142 (1–2):73–82.

230 230 Stieger B. Role of the bile salt export pump, BSEP, in acquired forms of cholestasis. Drug Metab Rev 2010; 42(3):437–45.

231 231 Shaw PJ, Ganey PE, Roth RA. Idiosyncratic drug‐induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity. Toxicol Sci 2010; 118(1):7–18.

232 232 Li AP. A review of the common properties of drugs with idiosyncratic hepatotoxicity and the “multiple determinant hypothesis” for the manifestation of idiosyncratic drug toxicity. Chem Biol Interact 2002; 142 (1–2):7–23.

233 233 Bachoual R, Dubreuil L, Soussy CJ, Tankovic J. Roles of gyrA mutations in resistance of clinical isolates and in vitro mutants of Bacteroides fragilis to the new fluoroquinolone trovafloxacin. Antimicrob Agents Chemother 2000; 44(7):1842–5.

234 234 Gootz TD, Zaniewski RP, Haskell SL, Kaczmarek FS, Maurice AE. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus. Antimicrob Agents Chemother 1999; 43(8):1845–55.

235 235 Lazarczyk DA, Goldstein NS, Gordon SC. Trovafloxacin hepatotoxicity. Dig Dis Sci 2001; 46(4):925–6.

236 236 Lucena MI, Andrade RJ, Rodrigo L, Salmeron J, Alvarez A, Lopez‐Garrido MJ, et al. Trovafloxacin‐induced acute hepatitis. Clin Infect Dis 2000; 30(2):400–1.

237 237 Chen HJ, Bloch KJ, Maclean JA. Acute eosinophilic hepatitis from trovafloxacin. N Engl J Med 2000; 342(5):359–60.

238 238 Sun Q, Zhu R, Foss FW, Jr., Macdonald TL. Mechanisms of trovafloxacin hepatotoxicity:studies of a model cyclopropylamine‐containing system. Bioorg Med Chem Lett 2007; 17 (24):6682–6.

239 239 Sun Q, Zhu R, Foss FW, Jr., Macdonald TL. in vitro metabolism of a model cyclopropylamine to reactive intermediate: insights into trovafloxacin‐induced hepatotoxicity. Chem Res Toxicol 2008; 21(3):711–9.

240 240 Shaw PJ, Ditewig AC, Waring JF, Liguori MJ, Blomme EA, Ganey PE, et al. Coexposure of mice to trovafloxacin and lipopolysaccharide, a model of idiosyncratic hepatotoxicity, results in a unique gene expression profile and interferon gamma‐dependent liver injury. Toxicol Sci 2009; 107(1):270–80.

241 241 Shaw PJ, Ganey PE, Roth RA. Tumor necrosis factor alpha is a proximal mediator of synergistic hepatotoxicity from trovafloxacin/lipopolysaccharide coexposure. J Pharmacol Exp Ther 2009; 328(1):62–8.

242 242 Shaw PJ, Hopfensperger MJ, Ganey PE, Roth RA. Lipopolysaccharide and trovafloxacin coexposure in mice causes idiosyncrasy‐like liver injury dependent on tumor necrosis factor‐alpha. Toxicol Sci 2007; 100(1):259–66.

243 243 Pascual A, Garcia I, Ballesta S, Perea EJ. Uptake and intracellular activity of trovafloxacin in human phagocytes and tissue‐cultured epithelial cells. Antimicrob Agents Chemother 1997; 41(2):274–7.

Текст предоставлен ООО «ЛитРес».

Прочитайте эту книгу целиком, купив полную легальную версию на ЛитРес.